Dapagliflozin: a sodium glucose cotransporter 2 inhibitor in development for type 2 diabetes.

Abd Tahrani, Anthony Barnett

Research output: Contribution to journalArticle

18 Citations (Scopus)


Type 2 diabetes mellitus (T2DM) is a growing worldwide epidemic. Patients face lifelong therapy to control hyperglycemia and prevent the associated complications. There are many medications, with varying mechanisms, available for the treatment of T2DM, but almost all target the declining insulin sensitivity and secretion that are associated with disease progression. Medications with such insulin-dependent mechanisms of action often lose efficacy over time, and there is increasing interest in the development of new antidiabetes medications that are not dependent upon insulin. One such approach is through the inhibition of renal glucose reuptake. Dapagliflozin, the first of a class of selective sodium glucose cotransporter 2 inhibitors, reduces renal glucose reabsorption and is currently under development for the treatment of T2DM. Here, we review the literature relating to the preclinical and clinical development of dapagliflozin.
Original languageEnglish
Pages (from-to)45-56
Number of pages12
JournalDiabetes Therapy: Research, treatment and education of diabetes and related disorders
Issue number2
Publication statusPublished - 1 Dec 2010


Dive into the research topics of 'Dapagliflozin: a sodium glucose cotransporter 2 inhibitor in development for type 2 diabetes.'. Together they form a unique fingerprint.

Cite this